David Kerr - Biography#

Professor David Kerr CBE MA MSc MD PhD DSc FRCP (Glasgow), FRCP (Edinburgh) FRCP (London) FRCGP (Hon) FACP FESMO FMedSci

David contributes to Oxford as Professor of Cancer Medicine, where he has worked with colleagues to build a new Institute for Cancer Medicine and Cancer Hospital. He is an Honorary Professor of Oncology in Sichuan and Oslo Universities.

He has an international reputation for the treatment of and research into cancer and the quality of his work has been recognised by the award of several national & international prizes, including the Harvard Global Health Catalyst: Distinguished Leader Award, in recognition of his many years of leadership in global health work. He has published over 400 papers, has an H-Index of 114 associated with over 56,000 citations and is in the top 1-2% of published cancer scientists.

He was elected Fellow of the Academy of Medical Sciences (2000), the European Academy of Cancer Sciences (2004), Honorary Fellow of Royal College of General Practitioners (2007), Honorary Fellow of Association of Cancer Physicians (2018), appointed Commander of the British Empire (2002) and was elected President of the European Society of Medical Oncology in 2010.

He has served as health adviser to two British Prime Ministers and has supported National Cancer planning in the UK, Sub Saharan Africa (Ghana, Nigeria and Kenya), India (http://www.indox.org.uk), is a Trustee of the AMAR Foundation (an award winning charity which supports and rebuilds the lives of some of the poorest communities in the world, with a current focus on the Yazidi people) and works in partnership with Chinese colleagues to improve the delivery of cancer care in China. He is Editor in Chief of The Oxford Textbooks of Oncology and Cancer Biology, was Editor in Chief of Annals of Oncology, established the Journal of Global Oncology and has initiated a new course in Oxford on Global Health Diplomacy ( https://conted.ox.ac.uk/courses/global-health-diplomacy ).

He has established a number of University biotech spin-outs, most recently Celleron Therapeutics, Oxford Cancer Biomarkers and SynOx.